Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen

Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of gastroenterology & hepatology Vol. 15; no. 4; p. 403
Main Authors Ekenel, Meltem, Avşar, Erol, Imeryüz, Neşe, Yüksel, Meral, Haklar, Goncagül, Kocakaya, Ozan, Tözün, Nurdan
Format Journal Article
LanguageEnglish
Published England 01.04.2003
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of celecoxib on gastric permeability in comparison with placebo and ibuprofen. We conducted a prospective, double-blind, cross-over study. This study is carried out at Marmara University Hospital. Twenty-five healthy subjects entered the study but 19 subjects completed the treatment. Subjects were randomized to celecoxib 100 mg twice daily, ibuprofen 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period. Gastric permeability was assessed by measuring urinary excretion of sucrose spectrophotometrically. Ibuprofen 600 mg twice daily produced greater increases in gastric permeability compared with placebo or celecoxib (geometric mean of urinary sucrose recovery was 59.15, 32.65 and 33.11 mg/h for ibuprofen, placebo and celecoxib, respectively) (P < 0.001). Celecoxib was generally better tolerated than ibuprofen. When compared with ibuprofen, celecoxib 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
AbstractList Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of celecoxib on gastric permeability in comparison with placebo and ibuprofen. We conducted a prospective, double-blind, cross-over study. This study is carried out at Marmara University Hospital. Twenty-five healthy subjects entered the study but 19 subjects completed the treatment. Subjects were randomized to celecoxib 100 mg twice daily, ibuprofen 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period. Gastric permeability was assessed by measuring urinary excretion of sucrose spectrophotometrically. Ibuprofen 600 mg twice daily produced greater increases in gastric permeability compared with placebo or celecoxib (geometric mean of urinary sucrose recovery was 59.15, 32.65 and 33.11 mg/h for ibuprofen, placebo and celecoxib, respectively) (P < 0.001). Celecoxib was generally better tolerated than ibuprofen. When compared with ibuprofen, celecoxib 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
Author Kocakaya, Ozan
Ekenel, Meltem
Imeryüz, Neşe
Yüksel, Meral
Haklar, Goncagül
Avşar, Erol
Tözün, Nurdan
Author_xml – sequence: 1
  givenname: Meltem
  surname: Ekenel
  fullname: Ekenel, Meltem
  organization: Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey
– sequence: 2
  givenname: Erol
  surname: Avşar
  fullname: Avşar, Erol
– sequence: 3
  givenname: Neşe
  surname: Imeryüz
  fullname: Imeryüz, Neşe
– sequence: 4
  givenname: Meral
  surname: Yüksel
  fullname: Yüksel, Meral
– sequence: 5
  givenname: Goncagül
  surname: Haklar
  fullname: Haklar, Goncagül
– sequence: 6
  givenname: Ozan
  surname: Kocakaya
  fullname: Kocakaya, Ozan
– sequence: 7
  givenname: Nurdan
  surname: Tözün
  fullname: Tözün, Nurdan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12655261$$D View this record in MEDLINE/PubMed
BookMark eNo1UMlOwzAQ9aGIlsIvoPmBgMdO4pgbqsoiVeoFpN4q23GoUWpHtgOq-HkilsNo5s1bpJkLMvPBW0IA6Q1SKW4ppSUTXBSMUk7LCRZTIc7IgsqqLGqJuzm5SOl92gqO4pzMkdVVxWpckK9111mTE4QOku2n0X1YWG13BQPnD067HOLEesgHC28q5egMDDYerdKud_n04xxNDMnegQITfI6h720LKY_tCT5dPsDQK2N1AOVbcHocYuisvyRnneqTvfrrS_L6sH5ZPRWb7ePz6n5TGM4RC1WbppTSoEBqjGKtNJzWglotK9twNmmqUujGVNNZAnldCpQNk7zlusa2ZEty_Zs7jPpo2_0Q3VHF0_7_C-wbP_ZgOg
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/00042737-200304000-00011
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 12655261
Genre Comparative Study
Clinical Trial
Randomized Controlled Trial
Journal Article
GroupedDBID ---
.-D
.Z2
0R~
4Q1
4Q2
4Q3
53G
5GY
5VS
6PF
71W
8L-
AAAAV
AAHPQ
AAIQE
AAMTA
AARTV
AASCR
AAUEB
AAWTL
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABVCZ
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFDTB
AFSOK
AFUWQ
AGINI
AHQNM
AHVBC
AINUH
AJIOK
AJNWD
AJNYG
AJZMW
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BQLVK
BS7
C45
CAG
CGR
COF
CS3
CUY
CVF
DIWNM
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F5P
FCALG
FL-
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
L-C
N9A
NPM
N~M
O9-
OAG
OAH
OCUKA
ODA
OJAPA
OLG
OLW
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVOZU
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
ZFV
ZZMQN
ID FETCH-LOGICAL-c3311-a6c8499c1710cca2d9c30670eb95e832311547b8c5126713647198293d3b61d42
ISSN 0954-691X
IngestDate Sat Sep 28 08:39:28 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3311-a6c8499c1710cca2d9c30670eb95e832311547b8c5126713647198293d3b61d42
PMID 12655261
ParticipantIDs pubmed_primary_12655261
PublicationCentury 2000
PublicationDate 2003-April
PublicationDateYYYYMMDD 2003-04-01
PublicationDate_xml – month: 04
  year: 2003
  text: 2003-April
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle European journal of gastroenterology & hepatology
PublicationTitleAlternate Eur J Gastroenterol Hepatol
PublicationYear 2003
SSID ssj0017317
Score 1.7118523
Snippet Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme...
SourceID pubmed
SourceType Index Database
StartPage 403
SubjectTerms Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Celecoxib
Cyclooxygenase 2
Double-Blind Method
Gastric Mucosa - metabolism
Humans
Ibuprofen - adverse effects
Ibuprofen - pharmacology
Isoenzymes - antagonists & inhibitors
Male
Membrane Proteins
Permeability
Prospective Studies
Prostaglandin-Endoperoxide Synthases
Pyrazoles
Stomach - drug effects
Sucrose - pharmacokinetics
Sucrose - urine
Sulfonamides - adverse effects
Sulfonamides - pharmacology
Title Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen
URI https://www.ncbi.nlm.nih.gov/pubmed/12655261
Volume 15
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1LbxMxEMetFCTEBfEu5SEf6KlalLW93l1uEKWqkBourRRO1drr0KjNbpUHEuVj8oWYGXsflCAVLqtonWwS-6fxeDz-D2NvwStOnRjmUTJTs0hlFjUglYlkZkor86KQBal9TvTRqfo0TaaDwc9e1tJmbd7Z663nSv5nVOEejCuekv2HkW0fCjfgNYwvXGGE4XqrMR53yRgrqmeDaUCjz9NIHMyr87mZUykdvx1w8LXAEh0WhYoXzqtz0-76aoMzpfOnnkPm-iW4oSQ86-O0lLhlar_RYDZY5zucINsW0w_-LX1fjZKfS6_zhJCdw-y3_i2SP74Aa0tx6GN32QSSkcBv-6NkPz_0CeBjn5biKV645Xfc4P84ouj3xPl3toh-8Y0Xq-a5y9CRTXRD9pJimjClinROZXU6i530yFQ986tIL-HPacHLDQ-psIhMkSGJxovO1Htb36PlakG4xEInidC3aL0h2N007bCdNEOjO8EAUtjYSiUVgW7_VkguCzqiW38e6tqGR95Y-5APdPKQPQiLF_7Bk_iIDVz1mN07DukZT9iPACSvZ7wFkhOQvAOS1xUHIHkAkveBpE96IN_zgnc4csKRI4484MgBR97i-JSdHo5PRkdRqO4RWSnjOCq0zWC5bWPwccGMiDK3uHwdOpMnDuYZlIFSqcksuKQ6jbHOQZxn4J2W0ui4VOIZu1PVldtlXMY2N7pIS13mKhMmSwtdinjorBNYwugFe-677ezKS7icNR2699eWl-x-x-MrdncGNsO9Bgd0bd7QkP4C5x1_ZQ
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+selective+COX-2+inhibitors+on+the+gastric+permeability+of+sucrose%3A+a+controlled+study+with+placebo+and+ibuprofen&rft.jtitle=European+journal+of+gastroenterology+%26+hepatology&rft.au=Ekenel%2C+Meltem&rft.au=Av%C5%9Far%2C+Erol&rft.au=Imery%C3%BCz%2C+Ne%C5%9Fe&rft.au=Y%C3%BCksel%2C+Meral&rft.date=2003-04-01&rft.issn=0954-691X&rft.volume=15&rft.issue=4&rft.spage=403&rft_id=info:doi/10.1097%2F00042737-200304000-00011&rft_id=info%3Apmid%2F12655261&rft_id=info%3Apmid%2F12655261&rft.externalDocID=12655261
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-691X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-691X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-691X&client=summon